Wolters Kluwer to Acquire AgileMD for Up to $100 Million

Wolters Kluwer announced on 13 November 2026 that Wolters Kluwer Health has signed an agreement to acquire AgileMD for up to $100 million. The release is datelined from Alphen aan den Rijn in the Netherlands and was published in the corporate section of the Wolters Kluwer newsroom. Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG, and it states 2025 annual revenues of €6.1 billion. Wolters Kluwer Health is the division that will own AgileMD once the transaction closes.

An upfront payment of $40 million and a deferred balance tied to performance

The consideration has two parts. $40 million is an upfront payment, and the balance is a deferred consideration contingent upon reaching certain performance targets. Together the two parts make up the headline of up to $100 million. The structure ties the larger share of the price to results: AgileMD’s owners receive value at the start, and the deferred consideration rewards the performance targets that Wolters Kluwer and AgileMD have agreed. The announcement describes AgileMD as having seen strong growth, which is the context in which the targets sit.

The announcement does not itemise the individual performance targets, and it does not need to for the headline to be clear. What it states is the ceiling of up to $100 million, the $40 million paid upfront and the principle that the remainder is earned. Readers who work on earn-out structures can use the Acquiry Earnout Modeller to see how a deferred share of this size behaves under different outcomes.

An expected return at or above the 8% cost of capital within 3-5 years

Wolters Kluwer also states the return it expects from the acquisition. The announcement says the acquisition is expected to achieve a return on invested capital (ROIC) at or above Wolters Kluwer’s after-tax weighted average cost of capital (WACC) of 8% within 3-5 years, and to have an immaterial impact on Wolters Kluwer adjusted earnings. Stating the return hurdle in the announcement gives shareholders and customers a clear yardstick: the company measures this acquisition against its own 8% cost of capital and gives a time frame for reaching it.

Customary closing conditions and a first-quarter 2027 timetable

The transaction is subject to customary closing conditions and other governmental approvals, and Wolters Kluwer expects it to close in the first quarter of 2027 or sooner. Counting from the announcement on 13 November 2026, the end of the first quarter of 2027 is the outer edge of the stated window, and the words “or sooner” leave room for an earlier completion. The workbook at the end of this report converts the window into a number of days so that the runway is visible at a glance.

AgileMD, based in San Francisco, was founded in 2011 and is led by co-founders Borna Safabakhsh, who is Co-Founder and CEO, and Dana Edelson, M.D., who is Chief Medical Officer. The company’s website carries the line “Better Outcomes. Lower Clinical Burden.” and describes a platform that lets care teams work with the electronic health record rather than for it. Its two solutions, eCART and Clinical Pathways, are organised under the headings Predict & Prioritize and Standardize & Improve.

Expected ARR of $7 million by year-end 2026

The announcement states that AgileMD has seen strong growth and is expected to reach annual recurring revenues (ARR) of $7 million by year-end 2026. It is the only financial metric of the target that the announcement gives, and it is the right one for a software business: recurring revenue is the measure that investors and acquirers use to compare subscription companies. It is also the denominator for the headline multiple in the workbook, where the headline of up to $100 million is divided by the $7 million of expected ARR.

The same announcement states that all 23 employees will be joining Wolters Kluwer Health. A team of that size carrying the footprint that AgileMD lists on its website is an unusually dense combination of people and installed base, and the workbook expresses it in two ways: the price per employee and the expected ARR per employee. Both use only the figures in the announcement.

A footprint of 400+ hospitals and 150,000+ clinical users

AgileMD’s website summarises its reach in six figures: 4,425,000+ patient encounters, 150,000+ clinical users, 400+ hospitals, 4,800+ pathways, 88+ publications and 14yr+ of experience. The site adds that it offers rapid, seamless implementation, with deployment “in days to weeks, not months to years”, and reporting and benchmarking that let health systems understand and drive practice patterns at the health system, facility, unit and provider level. The platform integrates with the EHR so that decision support sits inside the workflow clinicians already use.

From a University of Chicago start-up to an FDA-cleared product

AgileMD’s news page records the milestones that led to this agreement. On 20 October 2019 it published the headline “QuantHC Merges with AgileMD Uniting Clinical Pathways and AI”, which joined the two product lines that AgileMD offers today. On 5 May 2021 it recorded a partnership with BARDA to deploy an electronic health record integrated software tool for rapid and early identification of COVID-19 patients in need of emergency interventions, and on 12 October 2021 it announced a $2 million Phase II NIH SBIR grant to advance development of the eCART clinical decision support tool.

The most recent milestone on the page is regulatory. On 25 June 2024 AgileMD announced that it had received FDA clearance for eCART to predict in-hospital clinical deterioration across medical conditions. Coverage from the Polsky Center and Crain’s Chicago Business, which AgileMD lists on the same page, describes the product as born at UChicago. The company’s history therefore runs from academic research through grant funding and a merger to a cleared medical device, and it is that history that Wolters Kluwer Health is acquiring alongside the team.

eCART is the product that gives the announcement its mortality language. The Wolters Kluwer release describes it as a real-time AI-powered clinical surveillance engine that is FDA-cleared and designed to help reduce mortality rates. AgileMD’s website describes it as an FDA-cleared clinical deterioration early warning and workflow system that guides care teams to the highest-risk patients using industry-leading AI combined with actionable, embedded decision support for all-cause clinical deterioration.

Every hour of delayed ICU transfer raises the odds of hospital mortality by 3%

AgileMD states the clinical case in two sentences: for every hour of delayed ICU transfer, the odds of hospital mortality increase 3%, and when high-risk patients are transferred in a timely manner, their associated length of stay decreases by 2 days. The company says its partner health systems use eCART to improve these preventable outcomes, giving nurses and providers better information on patient status, more support with an acuity-based workflow and far fewer false alarms.

The product’s stated benefits follow the same logic: accurate and early risk stratification, timely and appropriate escalation of care, and decreased mortality, length of stay and direct variable costs. A nurse manager quoted on the site highlights the design choice behind the third benefit, describing a scoring approach in which the colour appears when a patient rises to the relevant level and otherwise stays out of the way.

Trained and tested on nearly 3 million encounters from 28 hospitals

AgileMD says eCART was developed out of more than a decade of research and clinical implementation, and that the analytic was trained and tested on nearly 3 million patient encounters from 28 hospitals across 6 health systems. It was retrospectively and prospectively validated on sepsis, COPD, CHF and COVID populations. The company also points to 85+ medical journal publications across eCART and Pathways, and its news page lists a head-to-head study with Yale in which co-founder Dr. Dana Edelson discussed hospital early warning scores in a JAMA+ AI interview on 3 January 2025.

Yale New Haven Health cites a 13% relative reduction in overall mortality

The clearest customer evidence on the news page is the Becker’s Health IT article of 19 August 2025. It states that Yale New Haven Health leverages eCART across its seven hospitals, and that Deborah Rhodes, MD, senior vice president and chief quality officer, told Becker’s how eCART gives clinicians time to intervene before critical events and the workflow to do so effectively. Since going live more than a year earlier, the system has yielded a 13% relative reduction in overall mortality (1.2% absolute), with especially significant improvements in outcomes related to sepsis.

The page lists a second customer conversation: on 28 April 2025, AVIA Marketplace published an episode in which Dr. Priti Patel, Chief Medical Information Officer at John Muir Health, and AgileMD CEO Borna Safabakhsh discussed how the eCART early warning system reduces mortality and improves patient outcomes. The FDA clearance, the BARDA support that the page records for the software device on 9 July 2024, and the customer evidence together give Wolters Kluwer Health a regulated, validated product to bring into the UpToDate family.

Pathways is the second AgileMD product named in the announcement. The Wolters Kluwer release says the Pathways product operationalizes local guidelines in the EHR workflow for consistency in care and outcomes measurement. AgileMD’s website describes the same idea from the clinician’s side: give care teams immediate access to the most updated protocols, streamlining order entry and documentation directly in their workflows.

Six capabilities that carry a guideline from the page to the order

AgileMD lists the capabilities that make a pathway usable at the bedside. The list below sets them out as the company describes them. Each capability moves a local guideline one step closer to the clinician’s action, which is the idea that Yaw Fellin refers to when he describes UpToDate’s expansion into embedded workflows and local guidelines.

• –Order directly from a pathway.
• –Align order sets and other decision support.
• –Embed labs and vitals from the EHR.
• –Generate clinical documentation.
• –Integrate clinical calculators.
• –Link to training and references.

Adult, pediatric and neonate topics across five care settings

AgileMD says more than 4,800 pathways are live at partner institutions, covering adult, pediatric and neonate topics in ambulatory, emergency, inpatient, ICU and women’s health settings. Its partners have published over 20 journal articles on their operational and outcome achievements with AgileMD Pathways. Teams can convert existing guidance or use AgileMD’s library of shared content to develop workflows customised for local needs and goals, and the pathways are deployed quickly without relying heavily on IT support.

The stated benefits of Pathways are rapid deployment and clinical consensus, timely and appropriate diagnostics, medication and discharge, and reduced throughput, length of stay and readmissions. A Chief Quality Officer at a 2,300+ bed health system is quoted on the site as saying that the system has driven adherence rates to guideline best practices through the roof with the pathway it deployed. The news page also lists a 16 July 2024 article on the 600 pathways that Yale New Haven Health takes to improved care delivery, and a 4 December 2024 article on UNC Health using AgileMD to address an IV fluid shortage.

A SOC-II and HIPAA compliant cloud engine with no on-site hardware

AgileMD describes the platform as secure, pragmatic and built to the toughest CIO standards. The AgileMD Cloud CDS engine is SOC-II and HIPAA compliant with industry security architecture, and the hosted platform requires no on-site hardware. It operates behind multiple layers of protection, encryption and network security, with advanced audit logging and monitoring services. For a health system’s IT team, those are the attributes that shorten security review, and they are part of what the company means by rapid implementation at scale.

The buyer’s side of the agreement starts with UpToDate. Wolters Kluwer’s UpToDate pages describe a suite of evidence-based solutions: UpToDate, UpToDate Lexidrug (formerly Lexicomp), UpToDate Patient and Member Engagement (formerly Emmi) and UpToDate Digital Architect. The personal and small group subscriptions are trusted by over 3 million health professionals worldwide, and the heart of UpToDate is over 7,600 expert clinicians, editors and reviewers who assemble the latest clinical, drug, and patient and member information with academic rigor.

More than 2,700 hospitals and more than 95% of U.S. Enterprise Edition customers

UpToDate Expert AI is described by Wolters Kluwer as evidence-based GenAI in clinical decision support. Since its introduction in September 2025, it has been adopted by more than 2,700 U.S. hospitals and health systems, representing more than 95% of U.S.-based UpToDate Enterprise Edition customers. That adoption is the base into which AgileMD will be introduced. The two figures, 2,700 hospitals for Expert AI and 400+ hospitals on AgileMD’s website, are placed side by side in the workbook as a footprint ratio.

Recognised by Frost & Sullivan after a review of over 60 CDS solutions

The UpToDate Enterprise page states that after analysing over 60 clinical decision support solutions, Frost & Sullivan’s Frost Radar 2025 recognised UpToDate as a leader in innovation and AI. The same pages record that UpToDate has been ranked number one Best in KLAS two years in a row for Patient Education and Patient-Driven Care Management, and that over 100 research studies agree UpToDate improves health outcomes. The Enterprise page also lists, among its benefits, access to the latest innovations including generative AI in clinical decision support, which is the area AgileMD joins.

A portfolio sharpened toward professional markets, from a €40 million divestment to AgileMD

The AgileMD agreement follows another portfolio decision by Wolters Kluwer within the same month. On 30 October 2026, the company announced an agreement to sell its German consumer tax business, Wolters Kluwer Steuertipps GmbH, to Buhl Data Service GmbH for €40 million. The release says the divestment allows Wolters Kluwer Tax & Accounting to further sharpen its strategic focus on professional markets, where the company sees the strongest opportunities for synergies, sustainable long-term growth and returns. Steuertipps is expected to have gross revenues of approximately €30 million (un-audited) in 2026.

Read together, the two announcements describe a company that is directing capital toward its professional solutions. Wolters Kluwer published its 2026 nine-month trading update on 4 November 2026 and a CFO interview on 6 November 2026, and the AgileMD announcement followed on 13 November 2026. The group serves customers in over 180 countries, maintains operations in over 40 countries and employs approximately 21,100 people worldwide, so the 23 people joining from AgileMD are a focused addition to a global organisation.

The announcement sets out the path to closing in a single sentence. The transaction, which is subject to customary closing conditions and other governmental approvals, is expected to close in the first quarter of 2027 or sooner. The window runs from the agreement on 13 November 2026 to the end of March 2027 at the latest, and it covers the period in which the parties complete the approvals that apply to a transaction of this type.

Milestones from a 2011 founding to a first-quarter 2027 close

The timeline below places the agreement among the milestones that the primary sources record, from AgileMD’s founding in 2011 to the expected close. It uses only dated facts from the announcement and from AgileMD’s own news page.

More advanced clinical pathways, built on UpToDate’s foundational capabilities

The announcement is specific about what the combined teams intend to build. Borna Safabakhsh states that, leveraging UpToDate’s foundational capabilities, AgileMD will accelerate and streamline the development and maintenance of more advanced clinical pathways for complex clinical decision-making support. Yaw Fellin states that with AgileMD, Wolters Kluwer is well positioned to help healthcare systems provide better patient care and extract more value from their tech investments.

The people who build the products join the buyer: all 23 AgileMD employees will be joining Wolters Kluwer Health, led by the two co-founders named in the announcement. The financial markers are equally clear. AgileMD is expected to reach $7 million of annual recurring revenue by year-end 2026, and Wolters Kluwer expects ROIC at or above its 8% WACC within 3-5 years. These are the figures against which the first years of the combined business will be measured.